A study of the combination of indinavir, ritonavir, enteric-coated ddI [didanosine] and d4T [stavudine] in nucleoside and non-nucleoside reverse transcriptase inhibitor experienced patients: an open-label study investigating differences between women and men

Trial Profile

A study of the combination of indinavir, ritonavir, enteric-coated ddI [didanosine] and d4T [stavudine] in nucleoside and non-nucleoside reverse transcriptase inhibitor experienced patients: an open-label study investigating differences between women and men

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2005

At a glance

  • Drugs Didanosine (Primary) ; Indinavir (Primary) ; Ritonavir (Primary) ; Stavudine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top